TD Asset Management
STML

TD Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

TD Asset Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-38,494
Closed -$590K – 1386
2019
Q2 		$590K Sell
38,494
-16,800
-30% -$243K ﹤0.01% 1154
2019
Q1 		$711K Buy
+55,294
New +$625K ﹤0.01% 1106
2014
Q2 		– Sell
-19,200
Closed -$391K – 1324
2014
Q1 		$391K Buy
19,200
+1,800
+10% +$43.7K ﹤0.01% 1097
2013
Q4 		$341K Sell
17,400
-1,500
-8% -$40K ﹤0.01% 1116
2013
Q3 		$856K Buy
18,900
+1,400
+8% +$45.7K ﹤0.01% 891
2013
Q2 		$417K Buy
+17,500
New +$279K ﹤0.01% 966

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TD Asset Management's STML Position: Q3 2019 in Review

TD Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 38,494 shares — an estimated $590K sold.

TD Asset Management first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $856K in Q3 2013. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • TD Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • TD Asset Management sold 38,494 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $590K.
  • TD Asset Management first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 6 quarters.
  • TD Asset Management's Stemline Therapeutics, Inc. position peaked at $856K in Q3 2013.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on TD Asset Management's 13F filing for Q3 2019, filed 7 Nov 2019.